Prescient Completes CAR-T Manufacturing Milestone
for Next Generation Immunotherapy Platform
KEY POINTS:
• Prescient has incorporated SpyTag into a range of binders for its three next
generation CAR-T programs
• Prescient has also received delivery of lentiviral vectors that will be used to
produce CAR-T cells expressing SpyCatcher
• The SpyTag binders and CAR-T cell expressing SpyCatcher are the novel
components for Prescient’s unique next generation OmniCAR platform
MELBOURNE Australia 24 June 2021: Prescient Therapeutics Limited (ASX: PTX) (“Prescient”),
a clinical stage oncology company developing personalised medicine approaches to cancer, today
announced the successful completion of the manufacturing and delivery of crucial components of
the OmniCAR platform for Prescient’s in-house programs of next-generation CAR-T therapies.
A range of binders against a variety of cancer targets, including CLL-1; CD33; Her2 and EGFRviii,
have been manufactured by a leading US antibody manufacturer. All binders have incorporated
SpyTag, which is required for covalent binding to immune cells (such as T-cells) in the OmniCAR
system.
Additionally, Prescient has also received delivery of lentiviral vectors that will be used to produce
CAR-T cells expressing SpyCatcher. Lentiviral vectors are a rate-limiting step in CAR-T
production. Together the SpyTagged binders and CAR-T cells expressing SpyCatcher form the
basis for the unique, modular OmniCAR platform.
The binders and lentiviral vectors have been delivered to the Peter MacCallum Cancer Centre
(Peter Mac) in Melbourne for construct testing and in vitro and in vivo development.
Prescient’s CEO and Managing Director, Steven Yatomi-Clarke said, "Demonstrating that
novel components can be manufactured is a crucial milestone in the development of an innovative
next-generation CAR platform like OmniCAR. Successfully producing binders for CLL-1; CD33;
Her2 and EGFRviii will enable our research team to produce CAR-T cells for our three in-house
programs. We are also pleased to have timely delivery of lentiviral vectors, which is rate-limiting in
manufacturing CAR-Ts and have proven to be a bottleneck for many developers.”
“Prescient’s research team at the Peter Mac has completed all the preparatory work in parallel,
and the delivery of the binders and vectors now enables the team to progress the development of
our in-house next-generation cell therapies.”
Prescient is developing OmniCAR programs for acute myeloid leukemia; Her2+ solid tumours,
including breast, ovarian and gastric cancers; and glioblastoma multiforme (the most common form
of brain cancer). In addition, Prescient has developed OmniCAR as a platform, allowing
collaborations and partnerships under licence with third parties wishing to incorporate OmniCAR
to enhance their respective cell therapies.
The OmniCAR platform is based on technologies developed at the University of Pennsylvania and
University of Oxford. Prescient has the worldwide license to commercialise the technologies.
Investor Briefing:
Prescient Therapeutics will host a briefing for shareholders and investors to discuss progress
with the OmniCAR research programs and Peter Mac partnership with Professor Phil Darcy from
Peter Mac; Prescient’s Director of Scientific Affairs, Dr Rebecca Lim; and Prescient CEO Steven
Yatomi-Clarke.
Date: Thursday, 1 July
Time: 11am AEST
Click here to register: https://prescienttherapeutics.investorportal.com.au/investor-briefing/
- Forums
- ASX - By Stock
- PTX
- Ann: PTX Completes CAR-T Manufacturing Milestone for OmniCAR
Ann: PTX Completes CAR-T Manufacturing Milestone for OmniCAR, page-3
-
- There are more pages in this discussion • 69 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PTX (ASX) to my watchlist
(20min delay)
|
|||||
Last
4.0¢ |
Change
0.001(2.56%) |
Mkt cap ! $32.21M |
Open | High | Low | Value | Volume |
4.0¢ | 4.0¢ | 4.0¢ | $8.763K | 219.0K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 58342 | 3.9¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
4.1¢ | 168410 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 58342 | 0.039 |
6 | 551544 | 0.038 |
8 | 387500 | 0.037 |
5 | 708916 | 0.036 |
4 | 303590 | 0.035 |
Price($) | Vol. | No. |
---|---|---|
0.041 | 168410 | 3 |
0.042 | 337500 | 2 |
0.043 | 504602 | 3 |
0.045 | 222151 | 4 |
0.047 | 13339 | 1 |
Last trade - 15.13pm 02/10/2024 (20 minute delay) ? |
Featured News
PTX (ASX) Chart |